Transdermal fluocinolone acetonide loaded decorated hyalurosomes cellulose acetate/polycaprolactone nanofibers mitigated Freund’s adjuvant-induced rheumatoid arthritis in rats
Journal of Pharmaceutical Investigation · 2025-01 · 55 (1) · 113-132
DOI: 10.1007/s40005-024-00693-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Investigation, online erschienen am 12.08.2024. Verfasst von Sammar Fathy ELhabal und 6 weiteren Autor:innen. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Science, Technology & Innovation Funding Authority.
Abstract (Originalsprache)
Purpose
This study aimed to develop a transdermal delivery system for fluocinolone acetonide (FLA), a corticosteroid used in treating inflammatory conditions like rheumatoid arthritis (RA), to overcome the limitations of oral administration, such as poor solubility and bioavailability.
Methods
FLA-loaded PEG decorated hyalurosomes (FLA-PHs) were fabricated using ethanol injection, incorporating various Brij® surfactants and different amounts of hyaluronic acid (HA) based on a full factorial design. The impact of independent variables, HA amount (mg) (X 1 ) and Brij type (X 2 ) were inspected for entrapment efficiency (EE%), particle size (PS), and zeta potential (ZP). The optimum FLA-PHs were then incorporated into ε-polycaprolactone (PCL) and cellulose acetate (CA) nanofibers to enhance sustained transdermal delivery (FLA-NFs).
Results
The optimum FLA-PHs exhibited EE% of 83.58 ± 0.69%, PS of 169.00 ± 1.41 nm, and ZP of -22.90 ± 0.14 mV. Morphological assessment of FLA-NFs showed promising results in terms of surface roughness. In a Freund-induced rat model of adjuvant-induced arthritis, transdermal treatment with FLA-NFs significantly improved joint histopathological analyses. Furthermore, it suppressed inflammatory markers such as mTORC1, TNF-α, and NF-κB while upregulating TRIM24 and the anti-inflammatory IL-10.
Conclusion
FLA-NFs present a promising strategy for enhancing the transdermal delivery of FLA for managing RA, offering potential improvements in efficacy and reduced systemic side effects compared to conventional oral administration.
Förderung
- The Science, Technology & Innovation Funding Authority
Zitieren
APA
ELhabal, S. F., El-Nabarawi, M. A., Hassanin, S. O., Hassan, F. E., Abbas, S. S., Gebril, S. M., & Albash, R. (2025). Transdermal fluocinolone acetonide loaded decorated hyalurosomes cellulose acetate/polycaprolactone nanofibers mitigated Freund’s adjuvant-induced rheumatoid arthritis in rats. Journal of Pharmaceutical Investigation, 55(1), 113-132. https://doi.org/10.1007/s40005-024-00693-8
Vancouver
ELhabal SF, El-Nabarawi MA, Hassanin SO, Hassan FE, Abbas SS, Gebril SM, et al. Transdermal fluocinolone acetonide loaded decorated hyalurosomes cellulose acetate/polycaprolactone nanofibers mitigated Freund’s adjuvant-induced rheumatoid arthritis in rats. Journal of Pharmaceutical Investigation. 2025;55(1):113-132. doi:10.1007/s40005-024-00693-8
BibTeX
@article{ELhabal2025,
author = {ELhabal, Sammar Fathy and El-Nabarawi, Mohamed A. and Hassanin, Soha Osama and Hassan, Fatma E. and Abbas, Samah S. and Gebril, Sahar M. and Albash, Rofida},
title = {Transdermal fluocinolone acetonide loaded decorated hyalurosomes cellulose acetate/polycaprolactone nanofibers mitigated Freund’s adjuvant-induced rheumatoid arthritis in rats},
journal = {Journal of Pharmaceutical Investigation},
year = {2025},
volume = {55},
number = {1},
pages = {113--132},
doi = {10.1007/s40005-024-00693-8}
}
EUVIMED